William Atallah
Urology · Brooklyn, NYNPI 1285992842
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $139,416 of the $190,592 with a category attached, or 73.1%. Boston Scientific accounts for 77.0% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $51,387, more than ten times the $1,673 reported in 2019. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $446.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$147K
- Cook Incorporated$27K
- Ambu Inc.$9K
- Cook Medical LLC$2K
- Ambu A/s$839
- Calyxo, Inc.$808
- plus $4K from 20 others
What the payments were for
- Consulting fees$27,75015%
- Speaking & faculty fees$139,41673%
- Travel & lodging$3,8322%
- Food & beverage$19,41610%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 312 | $146,761 |
| Cook Incorporated | 8 | $27,145 |
| Ambu Inc. | 5 | $9,086 |
| Cook Medical LLC | 20 | $2,447 |
| Ambu A/s | 1 | $839 |
| Calyxo, Inc. | 6 | $808 |
| Alnylam Pharmaceuticals Inc. | 18 | $545 |
| Urogen Pharma, Inc. | 6 | $463 |
| Procept Biorobotics Corporation | 2 | $384 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $300 |
| Bayer | 5 | $296 |
| Travere Therapeutics, Inc. | 5 | $216 |
| BD | 1 | $215 |
| Coloplast | 7 | $206 |
| Pfizer | 3 | $164 |
| Myovant Sciences Inc. | 7 | $149 |
| Novo Nordisk | 4 | $115 |
| Novo Nordisk Health Care AG | 1 | $114 |
| Merck | 5 | $108 |
| Johnson & Johnson(2 entities) | 3 | $87 |
| Dentsply IH Inc. | 2 | $34 |
| Progenics Pharmaceuticals, Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Dentsply IH AB | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$61,536
- S~Curve$22,520
- NEPHROMAX$3,600
- LithoVue$1,522
- GENERAL - THERAPIES$1,218
- GENERAL BPH$800
- CVAC Aspiration System$771
- Moses 550 D\F\L$743
- LITHOCLAST$679
- AquaBeam Robotic System$384
- NAVIGUIDE$350
- LITHO 150$254
- Nubeqa$243
- SWISS LITHOCLAST TRILOGY$237
- FIBER DUST$172
- Tria Firm$168
- GENERAL ERECTILE DYSFUNCTION$154
- PERCUTANEOUS TRACT KIT$153
- JELMYTO$150
- (815) Thiola$150
How this compares
$190,592 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 24 | $15,191 |
| Potassium Citrate ErPotassium Citrate | 111 | $11,051 |
| Tamsulosin Hcl | 133 | $1,529 |
| Finasteride | 76 | $1,145 |
| Chlorthalidone | 74 | $1,038 |
| Cefpodoxime Proxetil | 21 | $855 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 32 | $275 |
| Ciprofloxacin Hcl | 24 | $139 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $138 |
| Fluconazole | 14 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $24 | $15,19124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in Brooklyn
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.